NO943653L - Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon - Google Patents

Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Info

Publication number
NO943653L
NO943653L NO943653A NO943653A NO943653L NO 943653 L NO943653 L NO 943653L NO 943653 A NO943653 A NO 943653A NO 943653 A NO943653 A NO 943653A NO 943653 L NO943653 L NO 943653L
Authority
NO
Norway
Prior art keywords
prevention
treatment
monoclonal antibodies
hiv
neutralizing monoclonal
Prior art date
Application number
NO943653A
Other languages
English (en)
Norwegian (no)
Other versions
NO943653D0 (no
Inventor
Emilio A Emini
Anthony J Conley
George E Mark
L Syd Johnson
David S Pfarr
Original Assignee
Merck & Co Inc
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Medimmune Inc filed Critical Merck & Co Inc
Publication of NO943653D0 publication Critical patent/NO943653D0/no
Publication of NO943653L publication Critical patent/NO943653L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO943653A 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon NO943653L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (fr) 1992-04-01 1993-03-23 Anticorps monoclonaux humains recombines neutralisant le vih destines a prevenir et a traiter l'infection due au vih

Publications (2)

Publication Number Publication Date
NO943653D0 NO943653D0 (no) 1994-09-30
NO943653L true NO943653L (no) 1994-11-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943653A NO943653L (no) 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Country Status (19)

Country Link
EP (1) EP0577243A3 (fr)
JP (1) JPH06217791A (fr)
KR (1) KR950700761A (fr)
CN (1) CN1081716A (fr)
AU (2) AU3928593A (fr)
BG (1) BG99074A (fr)
CA (1) CA2093099A1 (fr)
CZ (1) CZ239694A3 (fr)
FI (1) FI944561L (fr)
HU (1) HUT70461A (fr)
IL (1) IL105145A0 (fr)
MX (1) MX9301858A (fr)
NO (1) NO943653L (fr)
NZ (1) NZ251582A (fr)
RU (1) RU94045907A (fr)
SK (1) SK116294A3 (fr)
WO (1) WO1993019785A1 (fr)
YU (1) YU22693A (fr)
ZA (1) ZA932308B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220114T3 (es) * 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
JP4922613B2 (ja) * 2003-02-20 2012-04-25 一般財団法人化学及血清療法研究所 モノクローナル抗体製剤の奏効性を向上させる方法
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
WO2015117008A2 (fr) * 2014-01-31 2015-08-06 The Rockefeller University Anticorps anti-vih de neutralisation large et épitope associé
JP6522732B2 (ja) * 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
EP4007605A4 (fr) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. Anticorps anti-fcrn et leurs procédés d'utilisation
WO2021227138A1 (fr) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) Anticorps monoclonal du nouveau coronavirus, ou partie de liaison à l'antigène de celui-ci
CN118666967B (zh) * 2024-03-06 2025-03-28 广东医保药业有限公司 多肽及其与头孢噻肟舒巴坦的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (fr) * 1987-10-09 1990-05-02 Repligen Corporation Polypeptides recombinants et leur utilisation, y compris un diagnostic pour le virus du SIDA
WO1990015078A1 (fr) * 1989-06-05 1990-12-13 Scott Charles F Jr ANTICORPS MONOCLONAUX HUMAINS DE LA gp 120 DU VIH-1¿MN?
EP0535154A4 (en) * 1990-06-15 1993-12-01 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (fr) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aamp-1, une proteine ayant des homologies locales avec les proteines env et nef de l'hiv-1

Also Published As

Publication number Publication date
EP0577243A3 (fr) 1994-11-02
FI944561A7 (fi) 1994-09-30
RU94045907A (ru) 1996-11-10
FI944561A0 (fi) 1994-09-30
NZ251582A (en) 1997-07-27
JPH06217791A (ja) 1994-08-09
FI944561L (fi) 1994-09-30
YU22693A (sh) 1997-01-08
BG99074A (bg) 1995-11-30
CA2093099A1 (fr) 1993-10-02
AU658987B2 (en) 1995-05-04
CZ239694A3 (en) 1995-07-12
KR950700761A (ko) 1995-02-20
HU9402824D0 (en) 1994-11-28
IL105145A0 (en) 1993-07-08
MX9301858A (es) 1994-03-31
EP0577243A2 (fr) 1994-01-05
AU3928593A (en) 1993-11-08
CN1081716A (zh) 1994-02-09
HUT70461A (en) 1995-10-30
NO943653D0 (no) 1994-09-30
SK116294A3 (en) 1996-11-06
WO1993019785A1 (fr) 1993-10-14
AU3563093A (en) 1993-10-07
ZA932308B (en) 1994-09-30

Similar Documents

Publication Publication Date Title
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
PT712863E (pt) Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica
DK0666868T3 (da) Anvendelse af anti-VEGF-antistoffer til behandling af cancer
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
NO20001671D0 (no) Naturlige humaniserte antistoff
CA2310888A1 (fr) Anticorps monoclonaux naturels humains
ES2145004T3 (es) Derivados de anticuerpos.
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DK0546076T3 (da) Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock
DE69333484D1 (de) Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
NO984851L (no) DHEA kombinasjonsterapi
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application